Neurocrine Biosciences (NBIX) Property, Plant & Equipment (Net) Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Property, Plant & Equipment (Net) Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.75 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.22 Bn | 39.57 Bn | 2.15 Bn | -18.34% |
| 3 | Zoetis | 31.40 Bn | 29.72 Bn | 1.05 Bn | 6.19% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -0.59% |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 41.67% |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | -7.68% |
| 7 | Neurocrine Biosciences | 15.61 Bn | 15.22 Bn | 935.80 Mn | -1.31% |
| 8 | Elanco Animal Health | 11.96 Bn | 11.43 Bn | 798.00 Mn | 3.98% |
| 9 | Dr Reddys Laboratories | 10.08 Bn | 9.91 Bn | - | 3.94% |
| 10 | Alkermes | 8.25 Bn | 7.60 Bn | 397.90 Mn | -8.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.31% |
| Mar 31, 2026 | 4.48% |
| Dec 31, 2025 | 8.72% |
| Sep 30, 2025 | 21.63% |
| Jun 30, 2025 | 14.48% |
| Mar 31, 2025 | 15.54% |
| Dec 31, 2024 | 16.67% |
| Sep 30, 2024 | 16.28% |
| Jun 30, 2024 | 22.10% |
| Mar 31, 2024 | 19.90% |
| Dec 31, 2023 | 20.82% |
| Sep 30, 2023 | 12.97% |
| Jun 30, 2023 | -1.80% |
| Mar 31, 2023 | -1.72% |
| Dec 31, 2022 | 0.00% |
| Sep 30, 2022 | 19.18% |
| Jun 30, 2022 | 33.60% |
| Mar 31, 2022 | 41.06% |
| Dec 31, 2021 | 31.39% |
| Sep 30, 2021 | 18.84% |